Acupuncture may help reduce symptoms and improve overall quality of life when used as a complementary therapy for myasthenia gravis (MG), but further research is needed to explore its effectiveness.
The FDA has approved the CD19+ B-cell targeted therapy inebilizumab-cdon (Uplizna, Amgen) for the treatment of adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine ...
Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new indication for its monoclonal antibody Uplizna. Thursday, the FDA greenlighted ...
Please provide your email address to receive an email when new articles are posted on . FDA approves inebilizumab-cdon for adults with anti-acetylcholine receptor and anti-muscle specific tyrosine ...
In the overall population, inebilizumab demonstrated a statistically significant improvement in MG-ADL total score compared with placebo. The Food and Drug Administration (FDA) has approved Uplizna ® ...
Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. The MINT trial ...
MG Lexicon will help patients and medical professionals communicate and share common information concerning the rare autoimmune, neuromuscular disease myasthenia gravis BOSTON, Dec. 5, 2025 ...
The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...
At the 2025 AANEM Annual Meeting, groundbreaking research was presented that advances the understanding and management of myasthenia gravis (MG), reports Dr Katherine Ruzhansky. One study identified ...
A new retrospective analysis compared clinical features of White, Hispanic, and African-American patients with MG who visited a single university-based clinic. After adjusting for covariates, the ...
World Myasthenia Gravis Day is celebrated every June 15 th. Myasthenia gravis (MG) is an autoimmune illness that affects approximately 1.5 to 2 million people globally. The disorder is characterized ...
Treatment with cemdisiran was associated with a statistically significant improvement in MG-ADL total score compared with placebo. Topline results were announced from a phase 3 trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results